Skip to main content

Cardiac care · in depth

Lipoprotein(a): The Test Most Malaysians Have Never Had

Lipoprotein(a), or Lp(a), is a genetically determined particle in your blood. About 1 in 5 people inherit a level high enough to meaningfully raise lifetime risk of heart attack and stroke, independently of LDL cholesterol. It is measured once in a lifetime. Almost no one in Malaysia is ever offered it.

Single blood collection tube with gold cap resting on a blank lab form with a family-tree diagram - Lp(a) is inherited.

Quick answer

Lipoprotein(a) is set by your genes, does not respond meaningfully to diet or exercise, and is an independent risk factor for heart attack, ischaemic stroke and calcific aortic stenosis. Roughly 20% of people have an elevated level. It needs measuring only once in a lifetime, with a single fasting blood test. The result changes how aggressively your other cardiovascular risk factors should be managed. If you have never had it measured, you should. At Hisential we order it as a standard part of cardiovascular risk assessment and explain exactly what the number means for you.

Medically reviewed by Dr. Azzim Emir, MBChB, Cert. Andrology (SMHS)

Last reviewed 1 May 2026 · Next review 1 November 2026

What lipoprotein(a) is, and why it matters

Lipoprotein(a), abbreviated Lp(a), is an LDL-like particle with an extra protein attached called apolipoprotein(a). Your level is set by the gene that codes for that protein. It is essentially fixed from childhood and does not change meaningfully with diet, exercise, statin therapy or weight loss.

Elevated Lp(a) does three things in the arteries: it accelerates atherosclerosis (like LDL), it promotes thrombosis (clotting), and it speeds up calcification of the aortic valve. Large genetic and outcome studies have established it as an independent, causal risk factor for myocardial infarction, ischaemic stroke and calcific aortic stenosis. Independent means it adds to the risk from LDL, blood pressure, smoking and diabetes, rather than being captured by them.

Roughly 20% of the global population inherits a level high enough to matter clinically. Despite this, it is essentially never ordered in routine Malaysian general practice.

Who should get tested

The European Society of Cardiology recommends measuring Lp(a) at least once in every adult's lifetime. In practice, the highest-yield groups are:

  • Anyone undergoing a structured cardiovascular risk assessment, particularly in the 30 to 60 age range.
  • Family history of premature cardiovascular disease (heart attack, stroke or sudden cardiac death in a first-degree relative before age 60).
  • Personal history of premature cardiovascular disease.
  • Elevated LDL cholesterol that has been difficult to explain or to control.
  • Familial hypercholesterolaemia or suspected familial hypercholesterolaemia.
  • Recurrent cardiovascular events despite well-controlled standard risk factors.

If you have ever had a structured lipid panel and Lp(a) was not on it, it was almost certainly missed.

How the test works

A single fasting venous blood draw. Result back within a few working days. No imaging, no follow-up sample needed, no annual recheck. Because the level is genetically fixed, one measurement is sufficient for life in the vast majority of people.

At Hisential the test is added on at the same visit as your wider lipid panel and risk assessment, so it does not require a separate appointment.

How to read your result

Lp(a) is reported in either mg/dL (mass) or nmol/L (particle concentration). The two units are not directly interchangeable, but the cut-offs map across.

  • Below 30 mg/dL (about 75 nmol/L): low; minor contribution to cardiovascular risk.
  • 30 to 50 mg/dL (about 75 to 125 nmol/L): borderline; modest contribution.
  • 50 to 90 mg/dL (about 125 to 225 nmol/L): elevated; meaningful independent risk.
  • Above 90 mg/dL (about 225 nmol/L): high; substantial independent risk, especially with any other risk factor.

The numbers are guidance, not a verdict. The clinical question is always: given this Lp(a), how should the rest of your plan change?

What to do if your Lp(a) is high

Lp(a) itself does not respond meaningfully to lifestyle or to statins. Niacin lowers it modestly but is not used for this purpose. Specific Lp(a)-lowering therapies (RNA-based agents like pelacarsen and olpasiran) are in advanced clinical trials but are not yet approved for routine use.

The practical strategy when Lp(a) is high is to intensify every other modifiable cardiovascular risk factor:

  • Lower LDL more aggressively. A high Lp(a) typically shifts you up one risk band, which tightens your LDL target. Statin plus ezetimibe, and if needed PCSK9 inhibitor therapy, get you there.
  • Treat blood pressure to target. Even small reductions matter more when baseline cardiovascular risk is higher.
  • Glycaemic and weight optimisation. Insulin resistance compounds Lp(a)-driven risk.
  • Smoking cessation. Non-negotiable.
  • Aspirin in selected patients. Considered in higher-risk men with elevated Lp(a) where bleeding risk allows.
  • Cascade screening. Because Lp(a) is inherited, first-degree relatives benefit from testing too.

Why once in a lifetime is enough

Lp(a) is determined by a single gene and is essentially stable from late childhood onwards. Apart from rare situations (pregnancy, severe systemic illness, kidney failure, thyroid disease), the number you have at 35 is the number you will have at 75. Repeat testing is unnecessary and a waste of money. What changes over time is the action you take in response to the result.

Selected references

  1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. (Recommends once-in-a-lifetime Lp(a) measurement in every adult.)
  2. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946.
  3. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331-2339. (Mendelian randomisation establishing Lp(a) as causal for coronary heart disease.)
  4. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503-512. (Lp(a) and calcific aortic stenosis.)
  5. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease (HORIZON trial design / AKCEA-APO(a)-LRx / pelacarsen). N Engl J Med. 2020;382(3):244-255.
  6. O'Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease (OCEAN(a) / olpasiran). N Engl J Med. 2022;387(20):1855-1864.

Frequently asked questions

FAQ

Frequently asked questions

Clear answers, written by our clinical team. Tap any question for its direct permalink, or reach out to your Personal Concierge for anything else.

  1. Why has no one ever tested my Lp(a)?

    It is not part of a standard lipid panel and is rarely ordered in Malaysian general practice. The evidence supporting once-in-a-lifetime Lp(a) testing has only become guideline-strength in the last several years, and uptake has been slow. At Hisential we include it routinely in cardiovascular risk assessment.

  2. If I cannot lower Lp(a), what is the point of measuring it?

    The number changes how aggressively the rest of your cardiovascular plan should be set, especially your LDL target, your blood pressure target and the threshold for adding ezetimibe or PCSK9 inhibitor therapy. It also flags first-degree relatives who should be tested. The action is on everything around Lp(a), not Lp(a) itself.

  3. Do I need to fast before the test?

    Fasting is not strictly required for Lp(a) itself, but because the test is almost always run alongside a full lipid panel, we ask you to fast 10 to 12 hours so both can be done from a single blood draw.

  4. Will future drugs that lower Lp(a) be useful for me?

    Possibly. RNA-based therapies (pelacarsen, olpasiran) are in advanced phase 3 trials and may receive regulatory approval in the coming years for very high-risk patients with elevated Lp(a). Knowing your level now puts you in a position to benefit early if and when these agents become available.

  5. Should my children be tested?

    Adult first-degree relatives (siblings, parents, adult children) of anyone with significantly elevated Lp(a) benefit from one-off testing. For children, testing is typically deferred to early adulthood unless there is a strong family history of very premature cardiovascular disease.

  6. Can I just order this test myself at a lab?

    You can, but the value of the test is in the interpretation and in the change to your wider cardiovascular plan, not in the number on its own. We recommend doing it as part of a structured risk assessment with a medical team that will actually act on the result.

Still have a question?

Your Personal Concierge replies within one business day - confidentially.

Continue exploring

Speak to your personal health concierge

One dedicated contact who coordinates your assessment, testing, treatment plan and follow-ups end-to-end. Confidential by default.